Endothelin-1 and receptor A: Predictive value for biochemical relapse on patients with advanced and metastatic prostate cancer;Endothéline-1 et récepteur A: valeur pronostique pour la reprise évolutive biologique dans l'adénocarcinome de prostate localement avancé et métastatique ganglionnaire

Progres en Urologie

Volumn 22, Issue 1, 2012, Pages 38-44

  Rotondo, S ^a   Menard, J ^a   Durlach, A ^b   Birembaut, P ^c   Staerman, F ^a  

^a SERVICE DE DERMATOLOGIE   (France)

^b REIMS UNIVERSITY HOSPITAL   (France)

^c Service d'Anatomopathologie   (France)

Author keywords

Endothelin 1; Metastasis; Prognosis; Prostate biopsy cores; Prostate cancer

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN A RECEPTOR;

AGED; ARTICLE; BIOPSY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; METABOLISM; PATHOLOGY; PROGNOSIS; PROSTATE; PROSTATE TUMOR; TUMOR RECURRENCE;

AGED; BIOPSY; ENDOTHELIN-1; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS; RECEPTOR, ENDOTHELIN A;

EID: 84355161698     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.purol.2011.08.038     Document Type: Article

References (17)

1. Messing E.M., Manola J., Yao J. Immediate versus deferred androgen deprivation treatment in patient with node positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006, 7:472-479.
2. Nelson J., Bagnato A., Battistini B. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003, 3:110-116.
3. Nelson J.B., Hedican S.P., George D.J., Reddi A.H., Piantadosi S., Eisenberger M.A., et al. Identification of endothéline-1 in the physiopathology of metastatic adenocarcinoma of the prostate. Nat Med 1995, 1(9):944-949.
4. Nelson J.B., Udan M.S., Guruli G., Pflug B.R. Endothelin-1 inhibits apoptosis in prostate cancer. Neoplasia 2005, 7(7):631-637.
5. Kobayashi S., Tang R., Wang B., Opgenorthh T., Stein E., Shapiro E., et al. Localization of endothelin receptors in human prostate. J Urol 1994, 151(3):763-766.
6. Perez T., Menard J., Joseph K., Birembaut P., Staerman F. Expression immunohistochimique de l'endothéline-1 sur biopsies prostatiques: marqueur pronostique d'adénocarcinome localement avancé ?. Prog Urol 2010, 20:364-368.
7. Soulie M., Barre C., Beudzeboc P., Chautard D., Cornud F., Eschwege P., et al. Recommandations 2004 en onco-urologie. Cancer de la prostate. Prog Urol 2004, 4:913-955.
8. Staerman F., Villers A. Conduite à tenir devant une hormono - indépendance. Prog Urol 2002, 12(1):37-43. les membres du comité de cancérologie de l'association française d'urologie.
9. Montironi R., Mazzucchelli R., Barbisan F., Stramazzotti D., Santinelli A., Beltran A.L., et al. Immunohistochemical expression of endothelin-1 and endothelin-A and endothelin-B receptors in high grade prostatic intraepithelial neoplasia and prostate cancer. Eur Urol 2007, 52:1682-1690.
10. Rosenblatt R., Valdman A., Liang Cheng M.D., Lopez-Beltran A., Montironi R., Ekman P., et al. Endothelin-1 expression in prostate cancer and high grade prostatic intraepithelial neoplasia. Anal Quant Cytol Histol 2009, 31:137-143.
11. Godara G., Cannon G.W., Cannon G.M., Bies R.R., Nelson J.B., Pflug B.R. Role of endothelin axis in progression to aggressive phenotype of prostate adenocarcinoma. Prostate 2005, 65(1):27-34.
12. Godara G., Pecher S., Jukic D.M., d'Antonio J.M., Akhavan A., Nelson J.B., et al. Distinct patterns of endothelin axis expression in primary prostate cancer. Urology 2007, 70(1):209-215.
13. D'Amico A., Altschuler M., Whittington R., Kao G., Malkowicz S.B., Wein A. The use of clinical parameters in an interactive statistical package to predict pathological features associated with local failure after radical prostatectomy for prostate cancer. Clin Perform Qual Health Care 1993, 1:219-222.
14. D'Amico A.V., Renshaw A.A., Cote K., Hurtwitz M., Beard C., Loffredo M., et al. Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease. J Clin Oncol 2004, 22:3726-3732.
15. D'Amico A.V., Whittington R., Malkowicz S.B., Schultz D., Fondurulia J., Chen M.H., et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 2000, 18:1164-1172.
16. Cheng L., Zincke H., Blute M.L., Bergstralh E.J., Scherer B., Bostwick D.G. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 2001, 91(1):66-73.
17. Schumacher M.C., Burkhard F.C., Thalmann G.N., Fleischmann A., Studer U.E. Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 2008, 54:344-352.